Fig. 1
From: HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
HSP90 inhibition enhances T-cell mediated killing of melanoma cells. a Tableau depiction of screen results from patient-derived cell line 2549. HSP90 inhibitors 1—17-DMAG, 2—BIIB021 and 3—17-AAG are highlighted. b Cleaved caspase 3 percentage following treatment with varying concentrations of ganetespib and autologous TILs in human melanoma cell lines 2549 and 2400. c Isobolograms depicting the synergism between ganetespib and T-cell killing. Points >1 indicate antagonism, points = 1 indicate additivity and points <1 indicate synergism. An unpaired two tailed Student t-test was performed with **P < 0.01; ****P < 0.0001. Data are a representation of at least two independent studies
